Pompe's disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ausems, 1999, Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling, Europ J Hum Genet, 7, 713, 10.1038/sj.ejhg.5200367
Hirschhorn, 2001, Glycogen Storage Disease Type II (GSDII), 3389
Lin, 1987, Pompe's disease in Chinese and prenatal diagnosis by determination of alpha-glucosidase activity, J Inherit Metabol Dis, 10, 11, 10.1007/BF01799482
Martiniuk, 1998, Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease, Am J Med Genet, 79, 69, 10.1002/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K
Poorthuis, 1999, The frequency of lysosomal storage diseases in The Netherlands, Hum Genet, 105, 151, 10.1007/s004399900075
Engel, 1973, The spectrum and diagnosis of acid maltase deficiency, Neurology, 23, 95, 10.1212/WNL.23.1.95
Van den Hout, 2003, The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature, Pediatrics, 112, 332, 10.1542/peds.112.2.332
Kishnani, 2006, A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease, J Pediatr, 148, 671, 10.1016/j.jpeds.2005.11.033
Slonim, 2000, Identification of two subtypes of infantile acid maltase deficiency, J Pediatr, 137, 283, 10.1067/mpd.2000.107112
Howell, 2006, Diagnostic challenges for Pompe disease: an under-recognized cause of floppy baby syndrome, Genet Med, 8, 289, 10.1097/01.gim.0000204462.42910.b8
Seifert, 1992, Development of obstruction to ventricular outflow and impairment of inflow in glycogen storage disease of the heart: serial echocardiographic studies from birth to death at 6 months, Am Heart J, 123, 239, 10.1016/0002-8703(92)90779-U
Gillette, 1974, Electrophysiological mechanism of the short PR interval in Pompe disease, Am J Dis Child, 128, 622
Ansong, 2006, Electrocardiographic response to enzyme replacement therapy for Pompe disease, Genet Med, 8, 297, 10.1097/01.gim.0000195896.04069.5f
Kamphoven, 2004, Hearing loss in infantile Pompe's disease and determination of underlying pathology in the knockout mouse, Neurobiol Dis, 16, 14, 10.1016/j.nbd.2003.12.018
Kishnani, 2006, Pompe disease diagnosis and management guideline, Genet Med, 8, 267, 10.1097/01.gim.0000218152.87434.f3
Kishnani, 2006, Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease, J Pediatr, 149, 89, 10.1016/j.jpeds.2006.02.035
Case, 2007, Fractures in children with Pompe disease: a potential long-term complication, Pediatr Radiol, 37, 437, 10.1007/s00247-007-0428-y
Laforet, 2000, Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation, Neurology, 55, 1122, 10.1212/WNL.55.8.1122
Wokke, 1995, Genotype-phenotype correlation in adult-onset acid maltase deficiency, Ann Neurol, 38, 450, 10.1002/ana.410380316
Winkel, 2005, The natural course of non-classic Pompe's disease; a review of 225 published cases, J Neurol, 252, 875, 10.1007/s00415-005-0922-9
Hagemans, 2005, Disease severity in children and adults with Pompe disease related to age and disease duration, Neurology, 64, 2139, 10.1212/01.WNL.0000165979.46537.56
Talsma, 2002, A rare presentation of childhood pompe disease: cardiac involvement provoked by Epstein-Barr virus infection, Pediatrics, 109, e65, 10.1542/peds.109.4.e65
Bembi, 2003, Efficacy of multidisciplinary approach in the treatment of two cases of nonclassical infantile glycogenosis type II, J Inherit Metab Dis, 26, 675, 10.1023/B:BOLI.0000005618.76542.ed
Kostera-Pruszczyk, 2006, Juvenile onset acid maltase deficiency presenting as a rigid spine syndrome, Neuromuscul Disord, 16, 282, 10.1016/j.nmd.2006.02.001
Hagemans, 2005, Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients, Brain, 128, 671, 10.1093/brain/awh384
Mellies, 2005, Respiratory failure in Pompe disease: treatment with noninvasive ventilation, Neurology, 64, 1465, 10.1212/01.WNL.0000158682.85052.C0
Mellies, 2001, Sleep-disordered breathing and respiratory failure in acid maltase deficiency, Neurology, 57, 1290, 10.1212/WNL.57.7.1290
Pellegrini, 2005, Respiratory insufficiency and limb muscle weakness in adults with Pompe's disease, Eur Respir J, 26, 1024, 10.1183/09031936.05.00020005
Hagemans, 2006, Course of disability and respiratory function in untreated late-onset Pompe disease, Neurology, 66, 581, 10.1212/01.wnl.0000198776.53007.2c
Makos, 1985, Acid maltase deficiency and basilar artery aneurysms: a report of a sibship, Neurology, 35, 193
Matsuoka, 1988, Late-onset acid maltase deficiency associated with intracranial aneurysm, J Neurol, 235, 371, 10.1007/BF00314237
Braunsdorf, 1987, Fusiform aneurysm of basilar artery and ectatic internal carotid arteries associated with glycogenosis type 2 (Pompe's disease), Neurosurgery, 21, 748, 10.1227/00006123-198711000-00030
Hers, 1963, alpha-Glucosidase deficiency in generalized glycogen storage disease (Pompe's disease), Biochem J, 86, 11, 10.1042/bj0860011
Reuser, 1978, Biochemical, immunological, and cell genetic studies in glycogenosis type II, Am J Hum Genet, 30, 132
Mehler, 1977, Residual acid maltase activity in late-onset acid maltase deficiency, Neurology, 27, 178, 10.1212/WNL.27.2.178
Umapathysivam, 2005, Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease, Clin Chim Acta, 36, 191, 10.1016/j.cccn.2005.05.025
Reuser, 1995, Glycogenosis type II (acid maltase deficiency), Muscle Nerve, 3, S61, 10.1002/mus.880181414
Okumiya, 2006, A new diagnostic assay for glycogen storage disease type II in mixed leukocytes, Mol Genet Metab, 88, 22, 10.1016/j.ymgme.2005.10.016
Jack, 2006, The use of acarbose inhibition in the measurement of acid alpha-glucosidase activity in blood lymphocytes for the diagnosis of Pompe disease, Genet Med, 8, 307, 10.1097/01.gim.0000217785.19262.9e
Umapathysivam, 2001, Determination of Acid alpha-Glucosidase Activity in Blood Spots as a Diagnostic Test for Pompe Disease, Clin Chem, 47, 1378, 10.1093/clinchem/47.8.1378
Chamoles, 2004, Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper, Clin Chim Acta, 347, 97, 10.1016/j.cccn.2004.04.009
Gelb, 2006, Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders, J Inherit Metab Dis, 29, 397, 10.1007/s10545-006-0265-4
Li, 2004, Direct Multiplex Assay of Lysosomal Enzymes in Dried Blood Spots for Newborn Screening, Clin Chem, 50, 1785, 10.1373/clinchem.2004.035907
Zhang, 2006, Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease, Genet Med, 8, 302, 10.1097/01.gim.0000217781.66786.9b
Meikle, 2006, Newborn screening for lysosomal storage disorders, Mol Genet Metab, 88, 307, 10.1016/j.ymgme.2006.02.013
Kallwass, 2007, Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots, Mol Genet Metab, 90, 449, 10.1016/j.ymgme.2006.12.006
Spada, 2006, High incidence of later-onset fabry disease revealed by newborn screening, Am J Hum Genet, 79, 31, 10.1086/504601
Besancon, 1985, Prenatal diagnosis of glycogenosis type II (Pompe's disease) using chorionic villi biopsy, Clin Genet, 27, 479, 10.1111/j.1399-0004.1985.tb00235.x
Martiniuk, 1986, Isolation of a cDNA for human acid alpha-glucosidase and detection of genetic heterogeneity for mRNA in three alpha-glucosidase-deficient patients, Proc Natl Acad Sci USA, 83, 9641, 10.1073/pnas.83.24.9641
Hoefsloot, 1988, Primary structure and processing of lysosomal alpha-glucosidase; homology with the intestinal sucrase-isomaltase complex, EMBO J, 7, 1697, 10.1002/j.1460-2075.1988.tb02998.x
Huie, 1994, A de novo 13 nt deletion, a newly identified C647W missense mutation and a deletion of exon 18 in infantile onset glycogen storage disease type II (GSDII), Hum Mol Genet, 3, 1081, 10.1093/hmg/3.7.1081
Huie, 2002, Homozygosity for Multiple Contiguous Single-Nucleotide Polymorphisms as an Indicator of Large Heterozygous Deletions: Identification of a Novel Heterozygous 8-kb Intragenic Deletion (IVS7–19 to IVS15–17) in a Patient with Glycogen Storage Disease Type II, Am J Hum Genet, 70, 4, 10.1086/339691
Van der Kraan, 1994, Deletion of exon 18 is a frequent mutation in glycogen storage disease type II, Biochem Biophys Res Comm, 203, 1535, 10.1006/bbrc.1994.2360
Boerkoel, 1995, Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II, Am J Hum Genet, 56, 887
Huie, 1994, Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (−13T−>G) mutation in a majority of patients and a novel IVS10 (+1GT−>CT) mutation, Hum Mol Genet, 3, 2231, 10.1093/hmg/3.12.2231
Montalvo, 2006, Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II, Hum Mutat, 27, 999, 10.1002/humu.20374
Kroos, 2007, Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype, Neurol, 68, 110, 10.1212/01.wnl.0000252798.25690.76
Shieh, 1998, Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect, Hum Mutat, 11, 306, 10.1002/(SICI)1098-1004(1998)11:4<306::AID-HUMU8>3.0.CO;2-S
Dagnino, 2000, Evidence for a founder effect in Sicilian patients with glycogen storage disease type II, Hum Hered, 50, 331, 10.1159/000022938
Hermans, 1994, The effect of a single base pair deletion (delta T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal alpha-glucosidase in patients with glycogen storage disease type II, Hum Mol Genet, 3, 2213, 10.1093/hmg/3.12.2213
Becker, 1998, The African origin of the common mutation in African American patients with glycogen-storage disease type II [letter], Am J Hum Genet, 62, 991, 10.1086/301788
Hasilik, 1980, Biosynthesis of lysosomal enzymes in fibroblasts. Synthesis as precursors of higher molecular weight, J Biol Chem, 255, 4937, 10.1016/S0021-9258(19)85585-0
Hasilik, 1980, Biosynthesis of lysosomal enzymes in fibroblasts. Phosphorylation of mannose residues, J Biol Chem, 255, 4946, 10.1016/S0021-9258(19)85586-2
Reuser, 1987, Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts, J Clin Invest, 79, 1689, 10.1172/JCI113008
Hermans, 2004, Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II, Hum Mutat, 23, 47, 10.1002/humu.10286
Slonim, 2006, Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy, Muscle Nerve, 35, 70, 10.1002/mus.20665
Slonim, 2006, Benign course of glycogen storage disease type IIb in two brothers: nature or nurture?, Muscle Nerve, 33, 571, 10.1002/mus.20473
Amalfitano, 1999, Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase, Proc Natl Acad Sci USA, 96, 8861, 10.1073/pnas.96.16.8861
Mah, 2007, Physiological Correction of Pompe Disease by Systemic Delivery of Adeno-associated Virus Serotype 1 Vectors, Mol Ther, 15, 501, 10.1038/sj.mt.6300100
McVie-Wylie, 2003, Multiple muscles in the AMD quail can be “cross-corrected” of pathologic glycogen accumulation after intravenous injection of an [E1-, polymerase-] adenovirus vector encoding human acid-alpha-glucosidase, J Gene Med, 5, 399, 10.1002/jgm.355
Pauly, 2001, Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease, Hum Gene Ther, 12, 527, 10.1089/104303401300042447
Sun, 2006, Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II, Mol Ther, 14, 822, 10.1016/j.ymthe.2006.08.001
Cresawn, 2005, Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II, Hum Gene Ther, 16, 68, 10.1089/hum.2005.16.68
Okumiya, 2007, Chemical chaperones improve transport and enhance stability of mutant alpha- glucosidases in glycogen storage disease type II, Mol Genet Metab, 90, 49, 10.1016/j.ymgme.2006.09.010
Parenti, 2007, Pharmacological Enhancement of Mutated alpha-Glucosidase Activity in Fibroblasts from Patients with Pompe Disease, Mol Ther, 15, 508, 10.1038/sj.mt.6300074
Raben, 1998, Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II, J Biol Chem, 273, 19086, 10.1074/jbc.273.30.19086
Bijvoet, 1998, Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease, Hum Mol Genet, 7, 53, 10.1093/hmg/7.1.53
2004, 1559
Kuma, 2004, The role of autophagy during the early neonatal starvation period, Nature, 432, 1032, 10.1038/nature03029
Engel, 1970, Acid maltase deficiency: comparison of infantile, childhood, and adult types, Neurology, 20, 382
Bijvoet, 1999, Pathological features of glycogen storage disease type II highlighted in the knockout mouse model, J Pathol, 189, 416, 10.1002/(SICI)1096-9896(199911)189:3<416::AID-PATH445>3.0.CO;2-6
Hesselink, 2002, Impaired performance of skeletal muscle in alpha-glucosidase knockout mice, Muscle Nerve, 25, 873, 10.1002/mus.10125
Hesselink, 2005, Age-related morphological changes in skeletal muscle cells of acid alpha-glucosidase knockout mice, Muscle Nerve, 33, 505, 10.1002/mus.20482
Winkel, 2003, Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy, Muscle Nerve, 27, 743, 10.1002/mus.10381
Fukuda, 2006, Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease, Mol Ther, 14, 831, 10.1016/j.ymthe.2006.08.009
Fukuda, 2006, Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease, Ann Neurol, 59, 700, 10.1002/ana.20807
Lynch, 2005, High-resolution light microscopy (HRLM) and digital analysis of pompe disease pathology, J Histochem Cytochem, 53, 63, 10.1177/002215540505300108
Thurberg, 2006, Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease, Lab Invest, 86, 1208, 10.1038/labinvest.3700484
Drost, 2005, Effects of non-contractile inclusions on mechanical performance of skeletal muscle, J Biomech, 38, 1035, 10.1016/j.jbiomech.2004.05.040
Hug, 1967, Lysosomes in type II glycogenosis. Changes during administration of extract from Aspergillus niger, J Cell Biol, 35, C1, 10.1083/jcb.35.1.C1
Baudhuin, 1964, An electron microscopic and biochemical study of type II glycogenosis, Lab Invest, 13, 1139
Ashwell, 1974, The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins, Adv Enzymol Relat Areas Mol Biol, 41, 99, 10.1002/9780470122860.ch3
Kaplan, 1977, Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts, Proc Natl Acad Sci USA, 74, 2026, 10.1073/pnas.74.5.2026
Fratantoni, 1968, Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts, Science, 162, 570, 10.1126/science.162.3853.570
Reuser, 1984, Uptake and stability of human and bovine acid alpha-glucosidase in cultured fibroblasts and skeletal muscle cells from glycogenosis type II patients, Exp Cell Res, 155, 178, 10.1016/0014-4827(84)90779-1
Van der Ploeg, 1988, Receptor-mediated uptake of acid alpha-glucosidase corrects lysosomal glycogen storage in cultured skeletal muscle, Pediatr Res, 24, 90, 10.1203/00006450-198807000-00021
Van der Ploeg, 1990, Rat heart perfusion as model system for enzyme replacement therapy in glycogenosis type II, Pediatr Res, 28, 344, 10.1203/00006450-199010000-00009
Van der Ploeg, 1991, Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice, J Clin Investig, 87, 513, 10.1172/JCI115025
Kikuchi, 1998, Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail, J Clin Invest, 101, 827, 10.1172/JCI1722
Bijvoet, 1999, Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II, Hum Mol Genet, 8, 2145, 10.1093/hmg/8.12.2145
Van Hove, 1996, High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease, Proc Natl Acad Sci USA, 93, 65, 10.1073/pnas.93.1.65
Raben, 2003, Enzyme replacement therapy in the mouse model of Pompe disease, Mol Genet Metab, 80, 159, 10.1016/j.ymgme.2003.08.022
Raben, 2002, Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme, Mol Ther, 6, 601, 10.1016/S1525-0016(02)90716-1
Ioannou, 1996, Fabry disease: enzyme replacement therapy in α-galactosidase A deficient mice, Am J Hum Genet, 59, A15
Sands, 2001, Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII, J Biol Chem, 276, 43160, 10.1074/jbc.M107778200
Sly, 2006, Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors, Proc Natl Acad Sci USA, 103, 15172, 10.1073/pnas.0607053103
Zhu, 2004, Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice, J Biol Chem, 279, 50336, 10.1074/jbc.M409676200
Zhu, 2005, Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice, Biochem J, 389, 619, 10.1042/BJ20050364
Barton, 1990, Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease, Proc Natl Acad Sci USA, 87, 1913, 10.1073/pnas.87.5.1913
Grabowski, 2004, Gaucher disease: lessons from a decade of therapy, J Pediatr, 144, 15, 10.1016/j.jpeds.2004.01.050
Grabowski, 1995, Enzyme therapy in type 1 Gaucher disease: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources, Ann Intern Med, 122, 33, 10.7326/0003-4819-122-1-199501010-00005
Wisselaar, 1993, Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation, J Biol Chem, 268, 2223, 10.1016/S0021-9258(18)53985-5
Van Hove, 1997, Purification of recombinant human precursor acid α-glucosidase, Biochem Mol Biol Int, 43, 613
Fuller, 1995, Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase, Euro J Biochem, 234, 903, 10.1111/j.1432-1033.1995.903_a.x
Bijvoet, 1998, Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice, Hum Mol Genet, 7, 1815, 10.1093/hmg/7.11.1815
Van den Hout, 2000, Recombinant human alpha-glucosidase from rabbit milk in Pompe patients, Lancet, 356, 397, 10.1016/S0140-6736(00)02533-2
Van den Hout, 2004, Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk, Pediatrics, 113, e448, 10.1542/peds.113.5.e448
Winkel, 2004, Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up, Ann Neurol, 55, 495, 10.1002/ana.20019
Klinge, 2005, Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial, Neuromuscul Disord, 15, 24, 10.1016/j.nmd.2004.10.009
Klinge, 2005, Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study, Neuropediatrics, 36, 6, 10.1055/s-2005-837543
Amalfitano, 2001, Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial, Genet Med, 3, 132
Hunley, 2004, Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease, Pediatrics, 114, e532, 10.1542/peds.2003-0988-L
Kishnani, 2007, Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease, Neurology, 68, 99, 10.1212/01.wnl.0000251268.41188.04
Raben, 2005, Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers, Mol Ther, 11, 48, 10.1016/j.ymthe.2004.09.017
Ing, 2004, Anaesthetic management of infants with glycogen storage disease type II: a physiological approach, Paediatr Anaesth, 14, 514, 10.1111/j.1460-9592.2004.01242.x
Cook, 2006, Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease, Genet Med, 8, 313, 10.1097/01.gim.0000217786.79173.a8
Muenzer, 2006, A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome), Genet Med, 8, 465, 10.1097/01.gim.0000232477.37660.fb
Barton, 1991, Replacement therapy for inherited enzyme deficiency. Macrophage-targeted glucocerebrosidase for Gaucher's disease, N Engl J Med, 324, 1464, 10.1056/NEJM199105233242104
Eng, 2001, Safety and efficacy of recombinant human alpha-galactosidase A: replacement therapy in Fabry's disease, N Engl J Med, 345, 9, 10.1056/NEJM200107053450102
Schiffmann, 2001, Enzyme replacement therapy in Fabry disease: a randomized controlled trial, JAMA, 285, 2743, 10.1001/jama.285.21.2743
Kakkis, 2001, Enzyme-replacement therapy in mucopolysaccharidosis I, N Engl J Med, 344, 182, 10.1056/NEJM200101183440304
Wraith, 2004, Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase), J Pediatr, 144, 581, 10.1016/j.jpeds.2004.01.046
Harmatz, 2004, Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), J Pediatr, 144, 574, 10.1016/j.jpeds.2004.03.018